Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 7/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 3/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486377 | 1.00 | KIT (0.36) | KITSYKDRD3HRH3HTR6 | |
| SCHEMBL19486749 | 0.95 | KIT (0.36) | KITSYKDRD3HRH3HTR6 | |
| SCHEMBL19486330 | 0.86 | BMPR1B (0.38) | KITDRD3HRH3RET | |
| SCHEMBL19486752 | 0.86 | BMPR1B (0.38) | KITDRD3HRH3RET | |
| SCHEMBL19459216 | 0.86 | RET (0.39) | KITSYKDRD3HTR6RET | |
| SCHEMBL19481766 | 0.85 | RET (0.39) | KITSYKRETJAK1JAK3 | |
| SCHEMBL19481699 | 0.85 | KIT (0.38) | KITRETJAK1JAK3 | |
| SCHEMBL19481706 | 0.85 | KIT (0.38) | KITRETJAK1JAK3 | |
| SCHEMBL19481701 | 0.85 | KIT (0.38) | KITRETJAK1JAK3 | |
| SCHEMBL19486477 | 0.84 | KCNH2 (0.38) | KITHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | KIT 27/4885SYK 1849/4885DRD3 4851/4885 |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | KIT 189/4885SYK 1634/4885DRD3 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.